Significant variation found in timing andselection of genetic tests for non--small-cell lung cancer

(Elsevier) Biomarker testing surveys specific disease-associated molecules to predict treatment response and disease progression; however its use has complicated the diagnosis of non-small-cell lung cancer (NSCLC). In a new study inThe Journal of Molecular Diagnosis, published by Elsevier, investigators provide for the first time a complete overview of biomarker testing, spanning multiple treatment lines, in a single cohort of patients.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news